Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma
Abstract Metabolic remodeling is the fundamental molecular feature of malignant tumors. Cancer cells require sufficient energy supplies supporting their high proliferative rate. MTHFD2, a mitochondrial one-carbon metabolic enzyme, is dysregulated in several malignancies and may serve as a promising...
Main Authors: | Juanfen Mo, Zhenzhen Gao, Li Zheng, Miaolong Yan, Min Xue, Jianqiu Xu, Yi Bao, Jiayuan Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-07-01
|
Series: | Cell Death Discovery |
Online Access: | https://doi.org/10.1038/s41420-022-01098-y |
Similar Items
-
Selectivity analysis of diaminopyrimidine-based inhibitors of MTHFD1, MTHFD2 and MTHFD2L
by: Vibhu Jha, et al.
Published: (2024-09-01) -
The catalytic mechanism of the mitochondrial methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2).
by: Li Na Zhao, et al.
Published: (2022-05-01) -
The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation
by: Petra Marttila, et al.
Published: (2024-09-01) -
Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy
in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01) -
The Studies of Prognostic Factors and the Genetic Polymorphism of Methylenetetrahydrofolate Reductase C667T in Thymic Epithelial Tumors
by: Miaolong Yan, et al.
Published: (2022-06-01)